Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
London, UK – 29 Aug 2015: A novel treatment algorithm for pulmonary arterial hypertension is launched today in new pulmonary hypertension guidelines from the European Society of Cardiology (ESC) and European Respiratory Society (ERS). The protocol aims to give patients the best chance of a good clinical outcome in a condition with dismal prognosis which puts severe limitations on patient choices including avoiding pregnancy, excessive physical activity and certain types of travel.
EMBARGO : 29 August 2015 at 08:00 BST
The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension are published online in the European Heart Journal1 and the European Respiratory Journal as well as on the ESC Website2. The document was written jointly by the ESC and the ERS and incorporates evidence accumulated since the previous joint guidelines were published in 2009.3Pulmonary hypertension is a condition in which blood pressure is raised in the pulmonary arteries, which supply blood to the lungs. It is a serious medical condition that leads to progressive right ventricular dysfunction with symptoms such as shortness of breath, fatigue, weakness, angina and syncope typically induced by exertion.The guidelines introduce a novel treatment algorithm for pulmonary arterial hypertension (PAH) and treatment tables outlining when to use recently approved drugs. Treatment strategies are based on the patient’s risk profile. Sequential and initial combination therapies are recommended following the emergence of new evidence and early consideration for lung transplantation is recommended for the first time. A novel treatment algorithm is also presented for chronic thromboembolic pulmonary hypertension (CTEPH) that includes surgical, medical and interventional strategies.Professor Nazzareno Galiè, ESC Chairperson of the guidelines Task Force, said: “Since the 2009 guidelines a huge amount of evidence has accumulated on the pharmacological treatment of patients with PAH. We have reconciled all the available data in a comprehensive treatment algorithm and in multiple tables that give recommendations for different patient risk profiles. The information is inclusive enough to be applicable in different healthcare systems with heterogeneous drug availability. The algorithm for CTEPH is more detailed and recommends specific imaging tests to better define the treatment strategy.”Clinical and haemodynamic classifications have been updated using new evidence on genetic and drug causes. Paediatric disorders are also classified and pulmonary vascular resistance (PVR) is included in the diagnosis of PAH. A new diagnostic algorithm starts with the echocardiographic probability of pulmonary hypertension (low, intermediate, high) and is followed by identification of the most common causes such as pulmonary hypertension due to heart diseases, lung diseases and CTEPH.“Pulmonary hypertension can involve multiple clinical conditions,” said Professor Marc Humbert, European Respiratory Society (ERS) Co-Chairperson of the guidelines Task Force. “The updated classifications and new diagnostic algorithm will help clinicians to better define an individual patient’s disease so that the most appropriate treatment can be given.”Expert centres are given a pivotal role in the management of pulmonary hypertension, starting with the diagnostic process. Professor Humbert said: “Right heart catheterization is recommended for confirming the final diagnosis of PAH and CTEPH and this technically demanding procedure provides more accurate information and has lower morbidity when performed in expert centres. Patients with established hypertension should be referred early to expert centres to ensure they are given the best care.”For the first time, the definition of satisfactory/unsatisfactory clinical responses to therapy is based on the change or maintenance of an individual patient risk profile. Nine clinical, functional, exercise, biochemical, imaging and haemodynamic parameters are assessed to calculate an estimated one year mortality of low (<5%), intermediate (5-10%), or high (>10%).Professor Galiè concluded: “The new data and the new recommendations included in this updated version of the pulmonary hypertension guidelines are intended to provide a practical approach to the management of these complex patients. In addition, the typical multidisciplinary approach will enhance the level of collaboration between various specialists and centres with different levels of expertise and experience.”ENDS
12015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2015. doi: 10.1093/eurheartj/ehv317 2ESC Guidelines on the ESC Website 3Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2009;30:2493–2537. doi:10.1093/eurheartj/ehp297
Guidelines at ESC CongressThe ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension will be featured in:• An ESC Guidelines 2015 overview session on August 30 at 08:30 • A Meet the Guidelines Task Force session on August 30 at 15:40 • A dedicated session on August 31 at 14:00 • An ESC Clinical Practice Guidelines 2015 Highlights session on September 2 at 09:00
SOURCES OF FUNDING: None.
DISCLOSURES: The disclosure forms of all experts involved in the development of these guidelines are available on the ESC website www.escardio.org/guidelines
ESC Press OfficeFor background information or assistance, please contact the ESC Press Office.For independent comment on site or interviews, please contact the ESC spokesperson coordinator: +44 7785 467 947
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2015ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2015 takes place 29 August to 2 September at ExCel London in London, UK. Access the scientific programme. More information is available from the ESC Press Office at email@example.com.To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2015. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
© 2017 European Society of Cardiology. All rights reserved